ASCO 2014: Clovis, AstraZeneca face off with EGFR, PARP inhibitors
This article was originally published in Scrip
Clovis Oncology and AstraZeneca are showing data for two sets of competing drugs at the 50th Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago, kicking off the first full day of abstract presentations with updated clinical trial results for Clovis's CO-1686 and rucaparib and AstraZeneca's AZD9291 and olaparib.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.